Chronotropic incompetence, beta-blockers, and functional capacity in advanced congestive heart failure: time to pace?

Eur J Heart Fail. 2008 Jan;10(1):96-101. doi: 10.1016/j.ejheart.2007.11.006. Epub 2007 Dec 21.

Abstract

Background: Chronotropic incompetence (CI) is often seen in subjects with chronic congestive heart failure (CHF). The prevalence of CI, its mechanisms and association with beta-blocker use as well as exercise capacity have not been clearly defined.

Methods and results: Cardiopulmonary exercise tolerance testing data for 278 consecutive patients with systolic CHF was analyzed. CI, defined as the inability to reach 80% of maximally predicted heart rate was present in 128 of 278 subjects (46%). The prevalence of CI was highest in those with most impaired exercise capacity (72, 48, and 24% for subjects with a VO(2) of <14.0, 14.0-20.0, and >20.0 ml/kg/min respectively; p=0.001). While subjects with CI had lower peak exercise heart rate (114 vs. 152 bpm), and lower peak VO(2) (15.4 vs. 19.9 ml/kg/min), they were equally likely to be on chronic beta-blocker therapy (74% vs. 71%; p=0.51). Heart rate and norepinephrine (NE) levels were measured during exercise in a separate cohort of 24 subjects with CHF. There was no difference in beta-blocker dose between subjects with and without CI, however, exercise induced NE release and Chronotropic Responsiveness Index, a measure of post-synaptic beta-receptor sensitivity to NE, were lower in subjects with CI (1687+/-911 vs. 2593+/-1451 pg/ml p=0.08; CRI 12.7+/-5.7 vs. 22.1+/-4.7, p=0.002).

Conclusions: CI occurs in >70% of subjects with advanced systolic CHF irrespective of beta-blocker use and is associated with a trend toward impaired NE release, post-synaptic beta-receptor desensitization and reduced exercise capacity.

MeSH terms

  • Adrenergic beta-Antagonists / administration & dosage*
  • Exercise / physiology*
  • Exercise Tolerance / physiology*
  • Female
  • Heart Failure* / blood
  • Heart Failure* / drug therapy
  • Heart Failure* / physiopathology
  • Heart Rate / drug effects
  • Heart Rate / physiology*
  • Humans
  • Male
  • Middle Aged
  • Norepinephrine / blood
  • Oxygen Consumption / physiology*
  • Stimulation, Chemical
  • Treatment Outcome

Substances

  • Adrenergic beta-Antagonists
  • Norepinephrine